Small Molecules with Novel Mechanisms
Total Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
427
NCT02717988
Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2015
Completion: Mar 31, 2016
NCT03315494
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
Start: Sep 22, 2016
Completion: Dec 21, 2016
NCT03564288
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
Start: Feb 23, 2018
Completion: Sep 2, 2021
NCT04057118
A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.
Phase: Phase 2
Start: Mar 20, 2019
Completion: Oct 13, 2020
NCT04056195
Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Start: Oct 11, 2019
Completion: Jan 10, 2023
NCT05042986
A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects
Phase: Early Phase 1
Start: Aug 10, 2021
Completion: Sep 29, 2021
NCT05971862
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors
Start: Jan 25, 2022
Completion: Oct 4, 2024
NCT06247345
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
Role: Collaborator
Start: Feb 6, 2024
Completion: Feb 28, 2026
Loading map...